spacer
home > pmps > winter 2017 > made in europe
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Made in Europe

When looking back at the news concerning active pharmaceutical ingredient (API) production and outsourcing published in the past seven years, it seems almost all market analysts were certain about one thing: a massive outflow of API activity to China and India. Some articles forecast an almost certain doom for Western manufacturers. In addition, second wave emerging markets like Brazil and Russia have also been mentioned as future additions to the API family, with the potential of taking over some of the established European production. On the other hand, a few reports focused on companies returning to Europe due to allegedly deteriorating quality and reliability of Indian and Chinese organisations. The market has been in flux, but it looks as if most members of that huge network have found a way to not only survive, but to grow or even thrive.

China and India have become dominant players in the global API market and their position is expected to grow. Businesses in these two countries are well aware of their strength and endeavour to take full advantage of it when it comes to their own markets as well as those overseas. The mixture of low wages for basic workers, sixday working weeks and many Americanand European-educated analysts with foreign experience are just some of the reasons as to why India has been playing such an important role in the business. For a lot of European companies, closing new deals with such competition in generic APIs is almost impossible.

Barter for a Deal

In many negotiations concerning API manufacturing, what the producers have to face on a daily basis is an arbitration centring on how close they can get to the price that has been offered to the customer by an Eastern firm. In the past, for APIs which were not produced by big pharmaceutical companies themselves, it was much easier to convince clients that those originating from Europe were meeting the highest possible standards, manufactured close to them and would be delivered in time. Those outsourcing often found this comforting as it usually meant that the facility was therefore in a convenient inspection range.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jiri Raska is the Commercial Director of Farmak, a traditional European generic API manufacturer in the Czech Republic. He has over 12 years of experience in the pharma industry and has been responsible for quality control, project management and business development. Jiriís current duties cover sales and the marketing of niche APIs to several countries around the world.
spacer
Jiri Raska
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

New research calls for pathology services to be better funded and prioritised


More info >>

White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

 
Industry Events

3D Cell Culture 2018

21-22 February 2018, Holiday Inn Kensington Forum, London UK

Building on the sell-out success of the launch event, SMi Group is delighted to announce the return of 3D Cell Culture, taking place on 21st and 22nd of February 2018, in London UK.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement